Krystal Biotech is a commercial-stage biotechnology company that focuses on discovering, developing, and commercializing genetic medicines for patients with rare diseases. It has commercialized VYJUVEK for the treatment of dystrophic epidermolysis bullosa (DEB) and is also developing various genetic medicines for other rare diseases.

Krystal Biotech, Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

COM:KRYSTALBIO

Krystal Biotech, Inc.

Last Close

182.29

22/11 21:00

Market Cap

4.74B

Beta: -

Volume Today

222.08K

Avg: -

name

homepage url

country

crunchbase url

employee count

sector

industry

revenue

Description

peer of

Metrics